Ozurdex dexamethasone intravitreal implant regulatory update

Allergan disclosed that last quarter it submitted an sNDA to FDA for Ozurdex 0.7 mg dexamethasone intravitreal implant to treat non-infectious, intermediate and posterior uveitis. Ozurdex is approved ...